IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

MARRA, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.828
EU - Europa 1.807
NA - Nord America 1.538
SA - Sud America 192
AF - Africa 62
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 4
Totale 5.442
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.473
CN - Cina 591
DE - Germania 587
SG - Singapore 530
IT - Italia 451
HK - Hong Kong 237
VN - Vietnam 178
SE - Svezia 161
BR - Brasile 152
GB - Regno Unito 130
RU - Federazione Russa 105
FR - Francia 95
NL - Olanda 77
IN - India 75
FI - Finlandia 52
CI - Costa d'Avorio 37
TR - Turchia 32
CA - Canada 30
IE - Irlanda 27
JP - Giappone 25
BD - Bangladesh 23
DK - Danimarca 21
ID - Indonesia 21
KR - Corea 21
MX - Messico 20
PH - Filippine 20
ES - Italia 18
AT - Austria 17
AR - Argentina 16
PL - Polonia 16
TW - Taiwan 12
AU - Australia 9
SA - Arabia Saudita 9
CH - Svizzera 8
EC - Ecuador 8
EG - Egitto 8
UA - Ucraina 8
ZA - Sudafrica 8
IQ - Iraq 7
IR - Iran 7
PK - Pakistan 7
BE - Belgio 6
NO - Norvegia 6
AM - Armenia 5
CL - Cile 5
TH - Thailandia 5
JM - Giamaica 4
KZ - Kazakistan 4
UZ - Uzbekistan 4
CO - Colombia 3
CZ - Repubblica Ceca 3
ET - Etiopia 3
HU - Ungheria 3
IL - Israele 3
LU - Lussemburgo 3
MY - Malesia 3
PE - Perù 3
RO - Romania 3
TT - Trinidad e Tobago 3
AL - Albania 2
AP - ???statistics.table.value.countryCode.AP??? 2
BB - Barbados 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
HN - Honduras 2
KE - Kenya 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
TN - Tunisia 2
UY - Uruguay 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BH - Bahrain 1
BS - Bahamas 1
CR - Costa Rica 1
EU - Europa 1
GE - Georgia 1
GR - Grecia 1
JO - Giordania 1
LT - Lituania 1
MA - Marocco 1
MD - Moldavia 1
ML - Mali 1
OM - Oman 1
PY - Paraguay 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
Totale 5.442
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 523
Ashburn 269
Singapore 247
Dallas 208
Hong Kong 195
Milan 135
Hefei 123
San Jose 111
Southend 86
Los Angeles 77
Beijing 71
Ho Chi Minh City 57
Fairfield 54
Chandler 53
Council Bluffs 50
New York 43
Santa Clara 38
Abidjan 37
Hanoi 37
Helsinki 34
Lauterbourg 30
Moscow 30
Bengaluru 29
Cambridge 29
Rome 28
Boardman 27
Dublin 27
Houston 26
Woodbridge 25
Wilmington 24
Shanghai 20
Princeton 18
São Paulo 18
Buffalo 17
Guangzhou 17
Phoenix 17
Seattle 16
Munich 15
Ann Arbor 14
Seoul 14
Amsterdam 13
Istanbul 13
Jakarta 13
Naples 13
Redwood City 13
Tokyo 13
Toronto 13
Genoa 12
Atlanta 11
Hangzhou 11
Shenyang 11
Vienna 11
Columbus 10
London 10
Mumbai 10
Cangzhou 9
Changsha 9
Da Nang 9
Dearborn 9
Düsseldorf 9
Turku 9
Chicago 8
Mexico City 8
Orem 8
Paris 8
Taipei 8
Tianjin 8
Turin 8
Wuhan 8
Buenos Aires 7
Fuzhou 7
Jinan 7
Lappeenranta 7
Zhengzhou 7
Ankara 6
Bergamo 6
Berlin 6
Bologna 6
Brooklyn 6
Des Moines 6
Florence 6
Nanjing 6
Nuremberg 6
Shenzhen 6
Toledo 6
Brussels 5
Central District 5
Dong Ket 5
Guayaquil 5
Haiphong 5
Iwasakichō 5
Jacksonville 5
Montreal 5
Padova 5
Rho 5
San Francisco 5
Stockholm 5
Trieste 5
Wroclaw 5
Yerevan 5
Totale 3.360
Salva come PNG Salva come JPEG
Nome #
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 510
Long-term disease-free survival in surgically-resected oral tongue cancer: a 10-year retrospective study 344
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure 311
Expression of tumor-associated antigens in breast cancer subtypes 296
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 272
Are all cyclin-dependent kinases 4/6 inhibitors created equal? 233
T cell Bispecific Antibodies to Bypass MHC Class I Loss in Breast Cancer 205
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer 200
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact 196
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer 190
What therapies are on the horizon for HER2 positive breast cancer? 187
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials 174
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors 156
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy 144
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 144
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments 142
Molecular tumor board in patients with metastatic breast cancer 142
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment 138
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience 137
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology 133
Pharmacological management of male breast cancer 129
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit 114
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study 111
Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer 105
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences 104
Multimodal histopathologic models stratify hormone receptor-positive early breast cancer 102
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis 100
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability 97
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer 95
Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer 90
PARP Inhibitors for Breast Cancer Treatment 85
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2 63
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials 60
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility 59
Toward precision medicine in inflammatory breast cancer 45
Artificial Intelligence in Thyroid Cytopathology: Diagnostic and Technical Insights 4
null 3
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer 1
Impact of breast cancer on sexuality and psycho-physical wellbeing: Survey analysis 1
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2 1
Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions 1
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study 1
Computational pathology in breast cancer: optimizing molecular prediction through task-oriented AI models 1
Publisher Correction: APOBEC3 mutagenesis drives therapy resistance in breast cancer 1
Corrigendum to: "Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis" [Eur J Cancer 145 (2021) 197-209] 1
Totale 5.628
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.056
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.056
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202164 0 0 0 0 0 0 0 0 0 0 16 48
2021/2022367 37 44 26 41 24 21 12 21 48 22 20 51
2022/2023230 40 38 19 18 15 33 5 18 24 1 14 5
2023/2024541 7 13 17 15 48 27 77 71 29 65 79 93
2024/20251.028 76 72 74 85 35 22 21 103 57 120 117 246
2025/20263.008 325 355 442 305 180 151 411 166 252 226 195 0
Totale 5.628